Changes in the plasma proteome at asymptomatic and symptomatic stages of autosomal dominant Alzheimer’s disease
出版年份 2016 全文链接
标题
Changes in the plasma proteome at asymptomatic and symptomatic stages of autosomal dominant Alzheimer’s disease
作者
关键词
-
出版物
Scientific Reports
Volume 6, Issue 1, Pages -
出版商
Springer Nature
发表日期
2016-07-06
DOI
10.1038/srep29078
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Alzheimer's disease biomarker discovery using SOMAscan multiplexed protein technology
- (2014) Martina Sattlecker et al. Alzheimers & Dementia
- Plasma phospholipids identify antecedent memory impairment in older adults
- (2014) Mark Mapstone et al. NATURE MEDICINE
- Imaging proteomics for diagnosis, monitoring and prediction of Alzheimer's disease
- (2014) Arash Nazeri et al. NEUROIMAGE
- Cerebral perfusion alterations and cerebral amyloid in autosomal dominant Alzheimer disease
- (2014) E. McDade et al. NEUROLOGY
- Symptom onset in autosomal dominant Alzheimer disease: A systematic review and meta-analysis
- (2014) D. C. Ryman et al. NEUROLOGY
- Plasma protein profiling of Mild Cognitive Impairment and Alzheimer’s disease using iTRAQ quantitative proteomics
- (2014) Fei Song et al. Proteome Science
- Amyloid β in hereditary cerebral hemorrhage with amyloidosis-Dutch type
- (2014) Juliette A. Kamp et al. REVIEWS IN THE NEUROSCIENCES
- Longitudinal Change in CSF Biomarkers in Autosomal-Dominant Alzheimer's Disease
- (2014) A. M. Fagan et al. Science Translational Medicine
- Functional Connectivity in Autosomal Dominant and Late-Onset Alzheimer Disease
- (2014) Jewell B. Thomas et al. JAMA Neurology
- Proteomic Changes in Cerebrospinal Fluid of Presymptomatic and Affected Persons Carrying Familial Alzheimer Disease Mutations
- (2012) John M. Ringman ARCHIVES OF NEUROLOGY
- Human apolipoprotein L1 (ApoL1) in cancer and chronic kidney disease
- (2012) Chien-An A. Hu et al. FEBS LETTERS
- Heparin Cofactor II, a Serine Protease Inhibitor, Promotes Angiogenesis via Activation of the AMP-activated Protein Kinase-Endothelial Nitric-oxide Synthase Signaling Pathway
- (2012) Yasumasa Ikeda et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study
- (2012) Eric M Reiman et al. LANCET NEUROLOGY
- Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease
- (2012) Randall J. Bateman et al. NEW ENGLAND JOURNAL OF MEDICINE
- STRING v9.1: protein-protein interaction networks, with increased coverage and integration
- (2012) Andrea Franceschini et al. NUCLEIC ACIDS RESEARCH
- Heparin Cofactor II as a Novel Vascular Protective Factor Against Atherosclerosis
- (2011) Ken-ichi Aihara et al. Journal of Atherosclerosis and Thrombosis
- Cerebrospinal Fluid Biomarkers in Alzheimer’s Disease Families with PSEN1 Mutations
- (2011) Juan Fortea et al. Neurodegenerative Diseases
- Plasma apolipoprotein E and Alzheimer disease risk: The AIBL study of aging
- (2011) V. B. Gupta et al. NEUROLOGY
- Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease
- (2011) Randall J Bateman et al. Alzheimers Research & Therapy
- Heme Scavenging and the Other Facets of Hemopexin
- (2009) Emanuela Tolosano et al. ANTIOXIDANTS & REDOX SIGNALING
- The ubiquitin–proteasome system in spongiform degenerative disorders
- (2008) Brandi R. Whatley et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- Plasma heparin cofactor II activity is an independent predictor of future cardiovascular events in patients after acute myocardial infarction
- (2008) Shao-Sung Huang et al. CORONARY ARTERY DISEASE
- Proteomic identification and early validation of complement 1 inhibitor and pigment epithelium-derived factor: Two novel biomarkers of Alzheimer's disease in human plasma
- (2008) Paul Cutler et al. Proteomics Clinical Applications
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started